Autopsy report · NCT00135733

A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus

“Pharmaceutical sponsor withdrew financial support.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months after it had already started.
• Ran for about 8 months before it stopped.
• 13 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Massachusetts General Hospital

Sponsor type

University, hospital or other

Conditions

Lichen Planus

Interventions

Amevive (Alefacept); Placebo

Participants

13

Sites

1

Countries

United States

Trials that died the same way

• Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Adjustable Gastric Banding
  “Sponsor withdrew funding.” (80% match in meaning)
• Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study
  “sponsor withdrew support” (80% match in meaning)
• BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
  “Withdrawal of sponsor support” (77% match in meaning)
• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
  “Funding withdrawn by sponsor” (77% match in meaning)
• Lucentis for New Onset Neovascular Glaucoma
  “Company withdrew funding/sponsorship” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.